Compare Stocks

→ Move Your Money Before May 1 (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$5.31 +2.3%	$4.22	$2.57 ▼ $7.00	$291.04M	1.86	549,756 shs	315,402 shs
RVX Resverlogix	C$0.06	C$0.06	C$0.05 ▼ C$0.15	C$16.33M	0.78	36,693 shs	26,153 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-2.63%	-4.24%	+26.28%	+58.72%	+21.83%
RVX Resverlogix	-8.33%	0.00%	0.00%	-21.43%	-59.26%

Protect Yourself While There’s Still Time … (Ad)

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	1.4908 of 5 stars	3.5	0.0	0.0	0.0	2.9	1.7	0.6
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	3.00	Buy	$13.00	144.82% Upside
RVX Resverlogix	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest CRMD, HZD, and RVX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	CRMD CorMedix	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
4/9/2024	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/13/2024	CRMD CorMedix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
1/31/2024	CRMD CorMedix	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$60K	4,850.69	N/A	N/A	$1.28 per share	4.15
RVX Resverlogix	N/A	N/A	C$0.00 per share	132.50	C($0.26) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$46.34M	-$0.92	N/A	N/A	N/A	N/A	-72.31%	-63.97%	5/20/2024 (Estimated)
RVX Resverlogix	-C$12.82M	-C$0.05	N/A	∞	N/A	N/A	N/A	-37.10%	5/9/2024 (Estimated)

Latest CRMD, HZD, and RVX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/1/2024	Q4 2023	RVX Resverlogix	N/A	-C$0.01	-C$0.01	-C$0.01	N/A	N/A
3/12/2024	Q4 2023	CRMD CorMedix	-$0.21	-$0.26	-$0.05	-$0.26	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	6.97	6.78
RVX Resverlogix	N/A	0.11	0.04

Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
RVX Resverlogix	N/A

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	3.60%
RVX Resverlogix	43.19%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	82	54.81 million	52.84 million	Optionable
RVX Resverlogix	19	272.17 million	N/A	Not Optionable

CRMD, HZD, and RVX Headlines

Source	Headline
	Resverlogix Announces Change to Its Board of Directors finance.yahoo.com - February 21 at 8:02 PM
	Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits finance.yahoo.com - January 11 at 10:03 AM
	Closing Bell: Resverlogix Corp flat on Tuesday (RVX) theglobeandmail.com - January 4 at 6:16 PM
	Resverlogix Corp. (RVX) Earnings Dates & Reports investing.com - December 19 at 7:28 PM
	Resverlogix Corp RVXCF morningstar.com - November 18 at 5:49 PM
	Resverlogix Corp RVX morningstar.com - November 1 at 11:18 AM
	Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX) theglobeandmail.com - October 18 at 7:46 AM
	Resverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy finanznachrichten.de - October 4 at 10:11 AM
	Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy finance.yahoo.com - October 4 at 10:11 AM
	Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight finance.yahoo.com - September 26 at 8:50 PM
	Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes finance.yahoo.com - August 29 at 10:13 AM
	Closing Bell: Resverlogix Corp up on Wednesday (RVX) theglobeandmail.com - August 24 at 3:35 PM
	Closing Bell: Resverlogix Corp flat on Monday (RVX) theglobeandmail.com - August 14 at 10:02 PM
	Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A) theglobeandmail.com - July 12 at 7:21 AM
	Resverlogix Announces Warrant Repricing and One-Year Extension finance.yahoo.com - June 29 at 11:09 PM
	Resverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders finanznachrichten.de - June 20 at 7:31 PM
	Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders finance.yahoo.com - June 20 at 7:31 PM
	Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients finance.yahoo.com - June 12 at 6:42 PM
	Canadian Investment Regulatory Organization Trading Halt - RVX.WT.A finance.yahoo.com - June 7 at 1:32 PM
	Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A) theglobeandmail.com - June 6 at 10:49 AM
	Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A) theglobeandmail.com - May 25 at 12:52 AM
	CBOE RUSSELL 2000 VOLATILITY IN (^RVX) finance.yahoo.com - May 18 at 12:38 AM
	Bromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzz news.google.com - May 13 at 3:47 PM
	Resverlogix : MD&A Q1 2023 - Marketscreener.com news.google.com - May 12 at 3:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CorMedix

NASDAQ:CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Resverlogix

TSE:RVX

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial